Apparent beneficial effects by nab-paclitaxel in the treatment of refractory metastatic ovarian carcinoma.
Agheli
Aref
A
Park
Sai Chang
SC
Huang
Chien-Jen
CJ
Wang
Jen C
JC
D018262:Adenocarcinoma, Clear Cell / Q000188:drug therapy*; D000368:Aged; D000418:Albumins / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D008875:Middle Aged; D010051:Ovarian Neoplasms / Q000188:drug therapy*; D017239:Paclitaxel / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*
C520255:130-nm albumin-bound paclitaxel; D000418:Albumins; D000970:Antineoplastic Agents; D017239:Paclitaxel